Navigation Links
Novel Mechanism for Long-Term Learning Identified by Carnegie Mellon Researchers
Date:1/3/2008

asy to monitor activity and changes. Limiting the mouse's ability to sense its surroundings through only one whisker causes a sensory imbalance leading to increased plasticity in the cortex.

"The neural mechanisms of learning and memory have been poorly understood," said Barth. "Establishing the relationship between NMDA and mGlu receptors will allow us to better understand how we learn and perhaps may help us better understand diseases where learning and memory is lost, as in Alzheimer's disease."

Coauthors of the study include Roger L. Clem, a graduate student in the Department of Biological Sciences and the Center for the Neural Basis of Cognition at Carnegie Mellon, and Tansu Celikel of the Department of Cell Biology at the Max Planck Institute for Medical Research. The study was funded by the National Institute of Drug Abuse.

About Carnegie Mellon: Carnegie Mellon is a private research university with a distinctive mix of programs in engineering, computer science, robotics, business, public policy, fine arts and the humanities. More than 10,000 undergraduate and graduate students receive an education characterized by its focus on creating and implementing solutions for real problems, interdisciplinary collaboration, and innovation. A small student-to-faculty ratio provides an opportunity for close interaction between students and professors. While technology is pervasive on its 144-acre Pittsburgh campus, Carnegie Mellon is also distinctive among leading research universities for the world-renowned programs in its College of Fine Arts. A global university, Carnegie Mellon has campuses in Silicon Valley, Calif., and Qatar, and programs in Asia, Australia and Europe. For more, see http://www.cmu.edu.


'/>"/>
SOURCE Carnegie Mellon University
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., PRINCETON, N.J., Nov. 25 /PRNewswire-FirstCall/...stage pharmaceutical company committed to discover... treat viral infections, reported financial result... September 30, 2009 Pharmasset held $58.4 million ...ts. ,, Pipeline Update and 2009 Highlights ,...
(Date:11/25/2009)..., CHICAGO and STAFA, Switzerland, Nov. 25 /PRNewsw...manufacturer of innovative hearing solutions, pres...dults Conference, focusing on the special needs of...ther leading experts in aging and audiology from a...ork everyday with older people with hearing loss f...
(Date:11/25/2009)... BRIDGEWATER, N.J., Nov. 25 The FD... (etravirine) tablets, a non-nucleoside reverse tr...ly NNRTI specifically indicated for use in treatme...ic failure with HIV-1 strains resistant to an NNRT...itional approval is based on 48-week data from two...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5Soy in the Diet May Protect Lung Function 50201 1The Psychology of Celebrity Worship 50198 1The Psychology of Celebrity Worship 50198 2The Psychology of Celebrity Worship 50198 3CareFusion Names Robert Friel to Board of Directors 50196 1CareFusion Names Robert Friel to Board of Directors 50196 2CareFusion Names Robert Friel to Board of Directors 50196 3
...ta from two Phase 3 trials show clinical success r...ibiotic therapy, WELLESLEY HILLS, Mass., March 13... announced today the presentation of,a poster enti...y for,Treating Infected Diabetic Foot Ulcers: A Ra...rial of Pexiganan Cream." The poster will be,prese...
...S, March 12 Eli Lilly and Company,(NYSE: LLY ), ...mpany,practices as alleged by the Connecticut Atto...issued March 11, 2008., The tone and content of t...rently be taking Zyprexa to treat a life-threateni...ed no acknowledgement of the,seriousness of schizo...
Other Medicine Technology:MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection 2MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection 3MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection 4MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection 5Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release 2Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release 3Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release 4
(Date:11/28/2009)...ariation believed to affect circadian rhythm, ,... New research suggests that an internal body clock...evelopment of bipolar disorder in children. , ...netic makeup of 152 children with bipolar disorder...swings, and 140 children without the disorder. The...
(Date:11/27/2009)...RD, Mass., Nov. 27 GSI G...upplier of precision technology products and semic...eeting of the Company,s shareholders has been sche...cation of the meeting will be announced in due cou...d a requisition notice from Stephen Bershad, a hol...
(Date:11/27/2009)... Biotech firm Replikins Ltd. today issued i...enomic data. It shows that the lethality of the v...uring the virus,s current outbreak in the spring o... 2.0 (s.d. 0.1). The H1N1 infectivity count, howev...Boston (PRWEB) November 27, 2009 -- Biotech firm R...
(Date:11/27/2009)...NCISCO, Nov. 27 The Gymb...lair Lambert, CFO/COO, will present at the NASDAQ ...he May Fair Hotel in London, England, on Wednesday...sten to a live broadcast of The Gymboree Corporati... to www.gymboree.com, click on "Our Company" at th...
(Date:11/27/2009)...LLY-SUR-SEINE, France, Nov. 27 Tea...al cycling team dedicated to ethical sporting and ...s, announced today that it will become Team Garmin...cal as a new sponsor of the team. Transitions Opti...e eyewear, offering the most advanced photochromic...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3
...s health plans in member satisfaction in four key ... Kaiser Permanente announced today that its member...n,s health plans highest in customer satisfaction ...west. These plans serve almost 7.5 million of Kai...
... include improved patient outcomes and , real-time... Somanetics Corporation (Nasdaq: SMTS ) announc... and Drug Administration (FDA) to expand the label...sed to manage therapies in patients above 2.5 kilo...
...l 16 Vion Pharmaceuticals, Inc. (OTC Bulletin Bo...ication (NDA) for its lead oncology therapeutic On...r review by the U.S. Food and Drug Administration ...gent for remission induction treatment for patient...
...Will Earn Decision Resources, Clinical Gold Standa...g to a New Report from Decision Resources , , WAL...the world,s leading research and advisory firms fo... that most influences their prescribing decisions ...
...and Vitamins Play an Important Role in Preventing ...rriors take note: Bursts of high-energy athletic a...lined by injury from overexertion. Overall wellnes...dy shows 91 percent of orthopedic specialists woul...
...d HIV business with the independence and sustainab...ment, access and shareholder value , - Renews focu... more new HIV treatments , - Equity split of 85% G...e entered into an agreement to create a new world-...
Other Medicine News:Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 2Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 3Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 4Health News:Somanetics Announces New FDA 510(K) Clearance 2Health News:Somanetics Announces New FDA 510(K) Clearance 3Health News:Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA 2Health News:Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA 3Health News:For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission 2Health News:For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission 3Health News:Video: Helping Weekend Warriors Stay in the Game 2Health News:Video: Helping Weekend Warriors Stay in the Game 3Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 2Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 3Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 4Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 5Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 6Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 7Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 8Health News:GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company 9
PAP Microwell ELISA
...EG-9200 is a Windows 2000 PC based EEG with high p...e and software. EEG-9200 provides high quality per... in the sleep lab or EEG lab. Quality EEG recordin...ICU. Neurofax has high performance, high sensitivi...
...pact is the first magnetic stimulator to offer the...c stimulation. It is designed to provide the simpl...stic routine (at the same time, it may also help r...ions without moving away from your patient). , ,...
Fidelity IAB Intra-Aortic Balloon Catheter
Medicine Products: